Status:
UNKNOWN
Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus
Lead Sponsor:
Tanta University
Collaborating Sponsors:
Menoufia University
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Diabetes mellitus (DM) is a complex metabolic disorder characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism. Despite the advancement in anti-diabetic drug ther...
Eligibility Criteria
Inclusion
- Glycated hemoglobin (HbA1c) between 7% and 9%.
- Body mass index ≥ 25 kg/m2
Exclusion
- Pregnant or nursing women.
- Type 1 diabetes mellitus.
- Liver disease (alanine aminotransferase \> 3 upper normal limit).
- Kidney disease (estimated glomerular filtration rate \< 60 ml/min/1.73 m2).
- Inflammatory bowel diseases.
- History of allergy and/or adverse reactions to the drugs used in the study.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT06010992
Start Date
October 1 2023
End Date
January 1 2025
Last Update
August 25 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of medicine, Tanta University
Tanta, El-Gharbia, Egypt, 31527
2
Faculty of Medicine, Menoufia University
Shibīn al Kawm, Menoufia, Egypt, 32511